TY - JOUR
T1 - High podoplanin expression in cancer cells predicts lower incidence of nodal metastasis in patients with lung squamous cell carcinoma
AU - Suzuki, Hanako
AU - Onimaru, Mitsuho
AU - Koga, Takaomi
AU - Takeshita, Masafumi
AU - Yano, Tokujiro
AU - Maehara, Yoshihiko
AU - Nakamura, Seiji
AU - Sueishi, Katsuo
N1 - Funding Information:
This work was supported by grants-in-aid (to K. S. and Y. Y.) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology. We would like to thank Hiroshi Fujii for his help with sectioning the tissue samples and histological experiments.
PY - 2011/2/15
Y1 - 2011/2/15
N2 - Podoplanin is expressed in a variety of malignant cells, and is generally regarded as a factor promoting tumor progression in conventional studies. Conversely, a recent clinicopathological study has revealed that low podoplanin in cancer cells was correlated with poor prognosis of patients with stage IB lung squamous cell carcinoma (LSCC).We here evaluated the clinicopathological relationship between cancer-cell podoplanin expression and clinicopathological parameters in 40 cases of LSCC (stage I-III).Immunohistochemical podoplanin expression significantly correlated with N classification and pathological stage, but not with other clinicopathological parameters. Notably, all 16 cases with high podoplanin expression unexceptionally exhibited pathological N0 status. Cases without nodal metastasis showed a significantly higher podoplanin-positive score. Furthermore, patients with high podoplanin expression exhibited a significantly longer survival time and disease-free time.These findings suggest that immunohistochemical analysis for podoplanin may serve as a marker of risk of nodal metastasis and prognosis in patients with LSCC.
AB - Podoplanin is expressed in a variety of malignant cells, and is generally regarded as a factor promoting tumor progression in conventional studies. Conversely, a recent clinicopathological study has revealed that low podoplanin in cancer cells was correlated with poor prognosis of patients with stage IB lung squamous cell carcinoma (LSCC).We here evaluated the clinicopathological relationship between cancer-cell podoplanin expression and clinicopathological parameters in 40 cases of LSCC (stage I-III).Immunohistochemical podoplanin expression significantly correlated with N classification and pathological stage, but not with other clinicopathological parameters. Notably, all 16 cases with high podoplanin expression unexceptionally exhibited pathological N0 status. Cases without nodal metastasis showed a significantly higher podoplanin-positive score. Furthermore, patients with high podoplanin expression exhibited a significantly longer survival time and disease-free time.These findings suggest that immunohistochemical analysis for podoplanin may serve as a marker of risk of nodal metastasis and prognosis in patients with LSCC.
UR - http://www.scopus.com/inward/record.url?scp=79551589012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551589012&partnerID=8YFLogxK
U2 - 10.1016/j.prp.2010.11.006
DO - 10.1016/j.prp.2010.11.006
M3 - Article
C2 - 21194851
AN - SCOPUS:79551589012
VL - 207
SP - 111
EP - 115
JO - Pathology Research and Practice
JF - Pathology Research and Practice
SN - 0344-0338
IS - 2
ER -
